Topical Corticosteroid Concerns Among Parents of Children with Psoriasis versus Atopic Dermatitis: A French Multicenter Cross-Sectional Study
Atopic dermatitis (AD) and psoriasis are chronic inflammatory cutaneous disorders for which the gold standard treatment is topical corticosteroids. Although fears about topical corticosteroids are known to be a primary cause of poor therapeutic adherence in AD, this has not been evaluated in psoriasis. TOPICOP is a helpful and easy-to-use tool for the evaluation of topical corticosteroid concerns (TCC). It may help clinicians improve adherence to treatment and correct misconceptions.
We aimed to compare the TCC of parents of children with psoriasis or AD using the TOPICOP scale and a visual analog scale (VAS).
We performed a cross-sectional multicenter study in nine French hospitals from 1 October 2015 to 31 May 2016. The TOPICOP scale was developed for patients with AD and comprises 12 questions to assess patients’ worries and beliefs about topical corticosteroids, with a maximum score of 36. We used a standardized questionnaire to collect epidemiologic and medical data, and the parents completed the TOPICOP scale and VAS (score 0–10).
A total of 122 children were enrolled (61 patients in each group). The mean Physician Global Assessment was 2.1 in the psoriasis group, and the mean SCORing AD index was 33.3 in the AD group. The TOPICOP score was 16.0 in the psoriasis group and 18.8 in the AD group (p = 0.10). The VAS score was 5.6 and 5.1 in the psoriasis and AD groups, respectively (p = 0.18). The mean TOPICOP score was higher if the mother answered (p < 0.0001; odds ratio 12.3; 95% confidence interval 9.2–15.5). In the AD group, the mean TOPICOP score was higher if follow-up for the child was as an outpatient (p = 0.018). In the psoriasis group, the mean TOPICOP score was higher if patients were seen for the first time (p = 0.047).
Using the TOPICOP questionnaire and a VAS, we found the level of TCC for the parents of pediatric patients with psoriasis to be similar to that for parents of pediatric patients with AD. As TCC is an issue in patients with psoriasis, future research is warranted to assess whether therapeutic education lessens TCC and improves treatment outcomes.
Compliance with Ethical Standards
No sources of funding were used to conduct this study or prepare this manuscript.
Conflicts of Interest
Sandra Moawad, Emmanuel Mahé, Hélène Aubert-Wastiaux, Alice Phan, Annabel Maruani, Christine Chiaverini, Christine Bodemer, Juliette Mazereeuw-Hautier, Audrey Lasek-Duriez, Catherine Droitcourt, Sébastien Barbarot, Alain Beauchet, and Anne-Claire Bursztejn have no conflicts of interest that are directly relevant to the content of this manuscript.
- 5.Mueller SM, Tomaschett D, Vogt DR, et al. Topical corticosteroid concerns from the clinicians’ perspective. J Dermatol Treat. 2016;7:1–5.Google Scholar
- 16.Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66:369–75.CrossRefPubMedGoogle Scholar
- 18.Gonzales F, Ramdane N, Delebarre-Sauvage C, et al. Monitoring of topical corticosteroid phobia in a population of parents with children with atopic dermatitis using the TOPICOP® scale: prevalence, risk facts and the impact of therapeutic patient education. J Eur Acad Dermatol Venereol. 2017;31:172–4.CrossRefGoogle Scholar